Cyclerion CFO Anjeza Gjino to resign; separation includes up to $430K in cash payments

Cyclerion Therapeutics, Inc.

CFO Anjeza Gjino to resign after Q3 2023 10-Q filing; resignation not due to any disagreement.
Receives $226K lump sum on separation, plus $102K each at 6- and 9-month anniversaries if still unemployed.
Vested stock options exercisable for 2 years post-separation; unvested options terminate on effective date.
Non-compete limited to 6 months; agreement includes confidentiality, non-disparagement, and general release.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anjeza Gjino

Chief Financial Officer

CYCN · Cyclerion Therapeutics, Inc.

Filed: October 23, 2023, 7:59 PM ET

On October 17, 2023, Cyclerion Therapeutics Inc. (“Cyclerion”) and Anjeza Gjino (“Ms. Gjino”), Cyclerion’s Chief Financial Officer, entered into a Separation and Release of Claims Agreement, dated such date (the “Agreement”), pursuant to which Ms. Gjino will resign from Cyclerion.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anjeza Gjino resigned as Chief Financial Officer at Cyclerion Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On October 17, 2023, Cyclerion Therapeutics Inc. (“Cyclerion”) and Anjeza Gjino (“Ms. Gjino”), Cyclerion’s Chief Financial Officer, entered into a Separation and Release of Claims Agreement, dated such date (the “Agreement”), pursuant to which Ms. Gjino will resign from Cyclerion.

View on SEC.gov

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-049190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.